Repotrectinib is a medication used in the treatment of certain types of cancer, specifically for patients with non-small cell lung cancer (NSCLC) or solid tumors that have a ROS1 gene rearrangement. It is a targeted therapy that works by inhibiting the ROS1 protein, which can drive cancer growth in affected cells.

Key Details:

• Class: Tyrosine Kinase Inhibitor (TKI)
• Mechanism: Repotrectinib targets and inhibits ROS1 fusion proteins, which are involved in tumor cell growth. By blocking ROS1 signaling, repotrectinib helps slow or stop the growth of cancer cells.
• Indications: Primarily used for the treatment of ROS1-positive NSCLC and other cancers harboring ROS1 gene rearrangements, especially those that are advanced or metastatic.

How it works Repotrectinib :

Repotrectinib binds to the ROS1 protein and blocks its activity, thereby preventing the growth of tumor cells that rely on ROS1 signaling. It is designed to target cancer cells that carry ROS1 gene fusions, a mutation present in a subset of NSCLC patients.

Administration:

• Form: Typically administered in oral tablet form.
• Dosage: The prescribed dosage is determined based on the individual’s condition, with adjustments made by the healthcare provider. It’s commonly taken once daily or as prescribed.

Side Effects:

Common side effects include:

• Fatigue
• Nausea
• Diarrhea
• Elevated liver enzymes
• Swelling or fluid retention
• Dizziness or headaches

Important Considerations:

• Repotrectinib is for ROS1-positive cancer patients, and testing is required before starting treatment to confirm the mutation.
• It is important for patients to be monitored regularly by a healthcare provider during treatment to manage side effects and assess the effectiveness of the drug.